Inventor · disambiguated record
Tonia J. Buchholz
Also filed as: BUCHHOLZ TONIA · BUCHHOLZ TONIA J · BUCHHOLZ TONIA JANE
7 granted patents·10 pending applications·3 citations·filing 2002–2025
74Inventor score
Top patents by PatentIndex Score
17 records- 0190US11666579B2Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2020·Granted Jun 6, 2023·2 cites·21 claims
- 0283US11390617B2Methods of treating non-Hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2020·Granted Jul 19, 2022·1 cites·31 claims
- 0380US2024400548A1Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2024·Application pending·0 cites
- 0478US12396995B2Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2023·Granted Aug 26, 2025·0 cites·34 claims
- 0578US2025352551A1Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2025·Application pending·0 cites
- 0677US12103923B2Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2022·Granted Oct 1, 2024·0 cites·23 claims
- 0776US12178822B2Methods of treating hematological malignancies using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dionCELGENE CORP·Filed 2023·Granted Dec 31, 2024·0 cites·26 claims
- 0875US2025017941A1Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2024·Application pending·0 cites
- 0968US11583536B2Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined useCELGENE CORP·Filed 2020·Granted Feb 21, 2023·0 cites·41 claims
- 1065US2022362255A1Methods of treating non-hodgkin lymphoma using 2-(2,6-dioxopiperidin-3-yl)-4-((2-fluoro-4-((3-morpholinoazetidin-1-yl)methyl)benzyl)amino)isoindoline-1,3-dioneCELGENE CORP·Filed 2022·Application pending·0 cites
- 1159US2009215093A1Compounds for enzyme inhibitionPROTEOLIX INC·Filed 2009·Application pending·0 cites
- 1253US12090147B2Combination therapy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2020·Granted Sep 17, 2024·0 cites·18 claims
- 1352US2024197871A1Combination of a car t cell therapy and an immunomodulatory compound for treatment of lymphomaJUNO THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1450US2006088471A1Compounds for enzyme inhibitionPROTEOLIX INC·Filed 2005·Application pending·0 cites
- 1549US2023149379A1Combination therapy for acute myeloid leukemiaCELGENE CORP·Filed 2021·Application pending·0 cites
- 1648US2019030018A1Compositions and methods of use of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamideCELGENE CORP·Filed 2018·Application pending·0 cites
- 1740US2003224469A1Methods and kits for assays utilizing fluorescence polarizationFiled 2002·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Tonia J. Buchholz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →